Here are five things to know:
1. The financing was led by HealthpointCapital.
2. The financing also included existing investors Smith & Nephew and TriVentures.
3. The proceeds will facilitate continued market adoption, clinical study programs and entry into the emerging markets.
4. OrthoSpace’s flagship product is InSpace, a disruptive technology for treating severe rotator cuff tears. The technology addresses a large growing market segment with limited treatment options for the continuum-of-care for rotator cuff injury.
5. The terms of the agreement were not disclosed.
“With five years of clinical experience and over 5,000 procedures completed, we have developed a loyal following among surgeons in Europe and Israel,” said Assaf Dekel, MD, OrthoSpace’s co-founder and medical director.
More articles on orthopedic devices:
47 orthopedic & spine devices receive FDA 510(k) clearance in April
Implanet gets FDA clearance for new JAZZ rod sizes—5 things to know
LDR COO sells 1.2k shares in $49k transaction: 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
